456Wire StoriesQuébec Nickel Corp. Announces Closing of the First Tranche of Its Previously Announced Private Placement
VANCOUVER, British Columbia–(BUSINESS WIRE)–Québec Nickel Corp. (CSE: QNI) (“Québec Nickel Corp.” or the “Company”) is pleased to announce that it has completed...
- 461Wire Stories
Québec Nickel Corp. Announces Closing of the First Tranche of Its Previously Announced Private Placement
VANCOUVER, British Columbia–(BUSINESS WIRE)–Québec Nickel Corp. (CSE: QNI) (“Québec Nickel Corp.” or the “Company”) is pleased to announce that it has completed...
- 547Wire Stories
ONE Championship Welcomes Stage Front VIP as Global VIP Experience Partner
Experiences for ONE’s U.S. Debut in 2023 to be Announced in Near Future SINGAPORE–(BUSINESS WIRE)–ONE Championship™ (ONE), the world’s largest martial arts...
- 578Wire Stories
ONE Championship Welcomes Stage Front VIP as Global VIP Experience Partner
Experiences for ONE’s U.S. Debut in 2023 to be Announced in Near Future SINGAPORE–(BUSINESS WIRE)–ONE Championship™ (ONE), the world’s largest martial arts...
- 457Wire Stories
Looking for a holiday gift? Choose Rokid Air and feel the thrill of carrying a big screen in your pocket
HANGZHOU, China–(BUSINESS WIRE)–The holiday season is back! How do you get your favorite entertainment whenever, wherever? During the holidays, augmented reality glasses...
- 627Wire Stories
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials
Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC showed an encouraging objective response rate of 32% and a manageable safety profile in patients...
- 668Wire Stories
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials
Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC showed an encouraging objective response rate of 32% and a manageable safety profile in patients...
- 612Wire Stories
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
? Company to Feature 15 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology ? Oral Presentations Include Updated Results from Phase...
- 646Wire Stories
Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction at Ophthalmology Innovation Summit XII
TEL AVIV, Israel & MELBOURNE, Australia–(BUSINESS WIRE)–Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for...
- 543Wire Stories
Inside information: Sievi Capital’s target company Nordic Rescue Group’s subsidiary ceases the manufacturing of rescue lifts
Sievi Capital Plc Inside information 9 December 2022 at 2:00 pm EET Inside information: Sievi Capital’s target company Nordic Rescue Group’s subsidiary...
